SG11201702132WA - A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases - Google Patents

A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases

Info

Publication number
SG11201702132WA
SG11201702132WA SG11201702132WA SG11201702132WA SG11201702132WA SG 11201702132W A SG11201702132W A SG 11201702132WA SG 11201702132W A SG11201702132W A SG 11201702132WA SG 11201702132W A SG11201702132W A SG 11201702132WA SG 11201702132W A SG11201702132W A SG 11201702132WA
Authority
SG
Singapore
Prior art keywords
bone metastasis
treating bone
diseases
medicaments
predicting
Prior art date
Application number
SG11201702132WA
Other languages
English (en)
Inventor
Josef Straub
Eike Staub
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG11201702132WA publication Critical patent/SG11201702132WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
SG11201702132WA 2014-09-17 2015-08-18 A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases SG11201702132WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051525P 2014-09-17 2014-09-17
PCT/EP2015/001701 WO2016041616A1 (fr) 2014-09-17 2015-08-18 Méthode de traitement de maladies provoquées par des métastases osseuses, médicaments à cet effet, et méthode de prédiction du résultat clinique du traitement de maladies provoquées par des métastases osseuses

Publications (1)

Publication Number Publication Date
SG11201702132WA true SG11201702132WA (en) 2017-04-27

Family

ID=53879459

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201702132WA SG11201702132WA (en) 2014-09-17 2015-08-18 A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases

Country Status (14)

Country Link
US (3) US10435472B2 (fr)
EP (1) EP3194972B1 (fr)
JP (2) JP7397569B2 (fr)
KR (1) KR20170055540A (fr)
CN (1) CN106714835A (fr)
AU (2) AU2015317411A1 (fr)
BR (1) BR112017004729A2 (fr)
CA (1) CA2961426C (fr)
ES (1) ES2897782T3 (fr)
IL (1) IL251077B (fr)
MX (1) MX2017003406A (fr)
RU (1) RU2017113001A (fr)
SG (1) SG11201702132WA (fr)
WO (1) WO2016041616A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170052690A (ko) 2014-09-17 2017-05-12 메르크 파텐트 게엠베하 고형암 및/또는 이의 전이 치료 방법, 그에 따른 약제, 및 고형암 및/또는 이의 전이 치료의 임상 결과 예측 방법
RU2017113001A (ru) * 2014-09-17 2018-10-17 Мерк Патент Гмбх Способ лечения метастазов в кости, предназначенные для этого медикаменты, и способ прогнозирования клинического исхода лечения метастазов в кости
CA3102632C (fr) * 2018-06-15 2023-07-25 Clearwater Seafoods Limited Partnership Stockage isole et ventile de fruits de mer
CA3112788A1 (fr) * 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Plate-forme de virus oncolytique permettant de traiter le cancer hematologique
KR102433986B1 (ko) * 2020-02-27 2022-08-22 주식회사 베르티스 암의 진단용 조성물
GB202100194D0 (en) * 2021-01-07 2021-02-24 Cambridge Entpr Ltd Inhibition of T-Cell activity

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK281142B6 (sk) 1991-03-06 2000-12-11 Merck Patent Gesellschaft Mit Beschr�Nkter Haftung Humanizovaná monoklonálna protilátka, expresné vektory a farmaceutický prostriedok
DK0719859T3 (da) 1994-12-20 2003-10-20 Merck Patent Gmbh Anti-alfa V-integrin monoklonalt antistof
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
MXPA03010007A (es) * 2001-05-02 2004-02-12 Novartis Ag USO DE BISFOSFONATOS EN EL TRATAMIENTO DE METASTASIS DE HUESO ASOCIADO CON CANCER DE PRoSTATA.
WO2003075958A1 (fr) 2002-03-11 2003-09-18 Takeda Chemical Industries, Ltd. Medicaments permettant de traiter une maladie dependant d'une hormone sexuelle
JP2004002321A (ja) * 2002-03-11 2004-01-08 Takeda Chem Ind Ltd 性ホルモン依存性疾患治療剤
EP1613966A2 (fr) * 2003-04-08 2006-01-11 Colotech A/S Procede de detection d'un cancer colorectal dans des echantillons humains
EP1973569B1 (fr) 2006-01-18 2013-05-22 Merck Patent GmbH Traitement specifique utilisant des ligands de integrine destine a traiter un cancer
WO2007103116A2 (fr) 2006-03-02 2007-09-13 Laboratory Corporation Of America Holdings Procédés et systèmes pour évaluer les facteurs de risques de santé par mesurage des dommages à l'adn et de sa réparation
PL2101805T3 (pl) * 2007-01-18 2013-04-30 Merck Patent Gmbh Ligandy integryn do stosowania w leczeniu nowotworów
EP2526967A1 (fr) 2007-07-17 2012-11-28 Merck Patent GmbH Anticorps hybrides à intégrine v anti-alpha modifiées
AU2009331955B2 (en) * 2008-12-23 2015-09-24 Merck Patent Gmbh Biomarkers for inhibitors with anti-angiogenic activity
US20120039805A1 (en) * 2009-02-20 2012-02-16 Pangea Biosciences, Inc. Therapeutics And Methods For Treating Neoplastic Diseases Comprising Determining The Level Of Caveolin-1 And/Or Caveolin-2 In A Stromal Cell Sample
CA2767914C (fr) * 2009-07-24 2020-02-25 Geadic Biotec, Aie. Marqueurs de cancer endometrial
WO2011033006A1 (fr) 2009-09-17 2011-03-24 F. Hoffmann-La Roche Ag Méthodes et compositions utilisées à des fins de diagnostic chez les patients atteints du cancer
EP2606349A4 (fr) * 2010-08-20 2014-04-30 Univ Jefferson Diagnostic du cancer et agent thérapeutique anticancéreux
JP6320042B2 (ja) * 2011-02-11 2018-05-09 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 前立腺癌治療のための抗アルファ−ｖインテグリン抗体
WO2012167028A2 (fr) * 2011-06-02 2012-12-06 The Regents Of The University Of California Compositions et méthodes de traitement du cancer et de maladies et états sensibles à l'inhibition de la croissance cellulaire
SG11201406184XA (en) * 2012-03-30 2014-10-30 Genentech Inc Diagnostic methods and compositions for treatment of cancer
WO2013152313A1 (fr) 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions et méthodes de traitement du cancer, de maladies et d'états sensibles à l'inhibition d'un facteur de croissance
US20140255413A1 (en) * 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
RU2017113001A (ru) * 2014-09-17 2018-10-17 Мерк Патент Гмбх Способ лечения метастазов в кости, предназначенные для этого медикаменты, и способ прогнозирования клинического исхода лечения метастазов в кости
KR20170052690A (ko) 2014-09-17 2017-05-12 메르크 파텐트 게엠베하 고형암 및/또는 이의 전이 치료 방법, 그에 따른 약제, 및 고형암 및/또는 이의 전이 치료의 임상 결과 예측 방법

Also Published As

Publication number Publication date
IL251077A0 (en) 2017-04-30
KR20170055540A (ko) 2017-05-19
AU2015317411A1 (en) 2017-04-27
ES2897782T3 (es) 2022-03-02
WO2016041616A1 (fr) 2016-03-24
RU2017113001A3 (fr) 2019-03-28
NZ730664A (en) 2023-12-22
US20170298133A1 (en) 2017-10-19
CN106714835A (zh) 2017-05-24
JP7397569B2 (ja) 2023-12-13
JP2021143183A (ja) 2021-09-24
RU2017113001A (ru) 2018-10-17
EP3194972B1 (fr) 2021-04-14
BR112017004729A2 (pt) 2017-12-05
US20190338037A1 (en) 2019-11-07
CA2961426C (fr) 2024-01-09
US11851492B2 (en) 2023-12-26
JP2017530970A (ja) 2017-10-19
IL251077B (en) 2022-05-01
AU2021261844A1 (en) 2021-12-02
EP3194972A1 (fr) 2017-07-26
US20220275094A1 (en) 2022-09-01
MX2017003406A (es) 2017-06-19
US11306146B2 (en) 2022-04-19
CA2961426A1 (fr) 2016-03-24
US10435472B2 (en) 2019-10-08

Similar Documents

Publication Publication Date Title
HK1246179A1 (zh) 治療視網膜疾病的方法
EP3212274A4 (fr) Ablation chimique et méthodes destinées à traiter diverses maladies
SG11201702132WA (en) A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
SG10202009849WA (en) Gene therapy for treating hemophilia a
HK1259345A1 (zh) 臨床目標治療計劃與優化
ZA201700371B (en) Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
HUE043819T2 (hu) Eljárás egy elõre gyártott termék továbbfeldolgozására, valamint ehhez tartozó elõre gyártott termék
HK1220015A1 (zh) 基因測序儀的控制裝置、方法和基因測序儀
EP3190413A4 (fr) Méthode de prédiction d'alternatives aux médicaments de traitement de la dépression
HK1257519A1 (zh) 用於 galgt2 基因治療的方法和物質
HK1247818A1 (zh) 治療疾病的方法
EP3147353A4 (fr) Procédé de production de cellules blastiques pancréatiques et agent de traitement d'une maladie du pancréas les contenant
PL3029005T3 (pl) Wyrób ogniotrwały, zestaw do wytwarzania wyrobu, sposób wytwarzania wyrobu oraz zastosowanie wyrobu
PL3247651T3 (pl) Pojemnik ze środkiem do traktowania oraz sposób jego wytwarzania
SG11201702135PA (en) A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof
PL2975010T3 (pl) Ditlenek cyrkonu, zastosowanie ditlenku cyrkonu i sposób wytwarzania wyrobu ogniotrwałego
IL259381B (en) Miravegron for the treatment of retinal diseases
HK1246271A1 (zh) 用於合成羥基-三甘油酯的方法及其用於預防和治療疾病的用途
PL3001843T3 (pl) Sposób obróbki produktu chmielowego i zastosowanie produktu chmielowego
GB201510676D0 (en) Novel diagnostic and therapeutic method
GB201806609D0 (en) A method of treatment and prognosis
GB201500555D0 (en) Method and device for the treatment of diseases
GB201616470D0 (en) Method of predicting the liklihood of success of gene therapy
GB201517565D0 (en) Treatment of genetic diseases
AU2015900620A0 (en) A method of treatment, diagnosis and/or prognosis